During the 2016 American Society of Hematology (ASH) meeting, I was interviewed by OBR to offer an opinion on how payers are implementing clinical pathways in how they provide coverage to patients with hematologic malignancies. Pathways are not always welcome by physicians and healthcare providers and there is always a debate about their value. In this video, I discuss how payers are approaching pathways. At the time of this taping, I was a VP and CMO at Cardinal Health Specialty Solutions.
Menu